A. B. Hancock Jr. Memorial Laboratory for Cancer Research, Departments of Biochemistry, Chemistry, and Pharmacology, Vanderbilt Institute of Chemical Biology, Center in Molecular Toxicology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.
Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853; Northeastern Collaborative Access Team, Argonne National Laboratory, Argonne, Illinois 60439.
J Biol Chem. 2014 Mar 7;289(10):6799-6808. doi: 10.1074/jbc.M113.517987. Epub 2014 Jan 14.
Oxicams are widely used nonsteroidal anti-inflammatory drugs (NSAIDs), but little is known about the molecular basis of the interaction with their target enzymes, the cyclooxygenases (COX). Isoxicam is a nonselective inhibitor of COX-1 and COX-2 whereas meloxicam displays some selectivity for COX-2. Here we report crystal complexes of COX-2 with isoxicam and meloxicam at 2.0 and 2.45 angstroms, respectively, and a crystal complex of COX-1 with meloxicam at 2.4 angstroms. These structures reveal that the oxicams bind to the active site of COX-2 using a binding pose not seen with other NSAIDs through two highly coordinated water molecules. The 4-hydroxyl group on the thiazine ring partners with Ser-530 via hydrogen bonding, and the heteroatom of the carboxamide ring of the oxicam scaffold interacts with Tyr-385 and Ser-530 through a highly coordinated water molecule. The nitrogen atom of the thiazine and the oxygen atom of the carboxamide bind to Arg-120 and Tyr-355 via another highly ordered water molecule. The rotation of Leu-531 in the structure opens a novel binding pocket, which is not utilized for the binding of other NSAIDs. In addition, a detailed study of meloxicam·COX-2 interactions revealed that mutation of Val-434 to Ile significantly reduces inhibition by meloxicam due to subtle changes around Phe-518, giving rise to the preferential inhibition of COX-2 over COX-1.
昔布类药物是广泛应用的非甾体类抗炎药(NSAIDs),但人们对其与靶酶环氧化酶(COX)相互作用的分子基础知之甚少。异丁昔布是 COX-1 和 COX-2 的非选择性抑制剂,而美洛昔康对 COX-2 具有一定的选择性。本研究报道了 COX-2 与异丁昔布和美洛昔康在 2.0 和 2.45 Å分辨率下的晶体复合物,以及 COX-1 与美洛昔康在 2.4 Å分辨率下的晶体复合物。这些结构揭示,昔布类药物通过两个高度配位的水分子,采用与其他 NSAIDs 不同的结合构象与 COX-2 的活性部位结合。噻嗪环上的 4-羟基与 Ser-530 通过氢键结合,昔布骨架的酰胺环的杂原子通过一个高度配位的水分子与 Tyr-385 和 Ser-530 相互作用。噻嗪的氮原子和酰胺的氧原子通过另一个高度有序的水分子与 Arg-120 和 Tyr-355 结合。结构中 Leu-531 的旋转打开了一个新的结合口袋,该口袋不用于其他 NSAIDs 的结合。此外,对美洛昔康·COX-2 相互作用的详细研究表明,将 Val-434 突变为 Ile 会由于 Phe-518 周围的细微变化而显著降低美洛昔康的抑制作用,从而导致 COX-2 对 COX-1 的选择性抑制。